Main Peptides

Launch Phase: Early access Pricing Sitewide
Sale!
GLOW
GLOW - Image 2
, , , ,

GLOW

Original price was: $199.99.Current price is: $149.99.

Earn up to 150 points.

Complimentary Bacteriostatic Water on orders $300+ (automatically added at checkout)

- +
Add to WishlistRemove from Wishlist

Note: Shipped In Freeze Dried Lyophilized Form – Requires Bacteriostatic Water for Reconstitution (Sold Here)

Vial Size: 3 mL (Can hold up to 3 mL of BAC Water)

FREE shipping on orders over $250+
Guaranteed Safe Checkout

GLOW Blend is a targeted peptide formulation combining GHK-Cu (50 mg), TB-500 (10 mg), and BPC-157 (10 mg) per unit, designed to support in vitro research on skin regeneration, cellular repair, and extracellular matrix modulation. GHK-Cu is a copper-binding tripeptide widely studied for its role in collagen production, tissue remodeling, and gene regulation. TB-500 and BPC-157 are synthetic peptides explored for their synergistic effects on angiogenesis, inflammation control, and fibroblast migration. This blend is ideal for research into dermal repair and regenerative signaling pathways.

Weight .06 kg
Size

70 mg
Shelf Life

24 months
Storage

Lyophilized: freeze at ?20 °C (?4 °F)
Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F); use within 4-6 weeks.
Molecular Formula

C62H98N16O22 C38H68N10O14 (TB-500 fragment sequence) C28H48CuN12O8
PubChem CID

9941957 http://www.pubchem.ncbi.nlm.nih.gov/compound/9941957 62707662 http://www.pubchem.ncbi.nlm.nih.gov/compound/62707662 133697840 http://www.pubchem.ncbi.nlm.nih.gov/compound/133697840
Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For research purposes only. Not for human consumption.

You may also like…

  • Sale!

    KPV

     Immune Research Price range: $49.99 through $69.99
  • Sale!

    Epitalon

     Cellular Research Price range: $49.99 through $199.99
  • Sale!

    NAD+

     Cellular Research Price range: $49.99 through $109.99
  • Sale!

    Glutathione

     Cellular Research Price range: $39.99 through $79.99

Your wishlist is currently empty!

Wishlist
View Wishlist

Research Compound Profile

GLOW

Also known as: Glow Stack · Glow Blend · Skin Rejuvenation Stack Category: Regenerative Peptide Blend Clinical Status: Preclinical Research (Components) FDA Status: Not Approved · Investigational

A triple-peptide combination of BPC-157, TB-500, and GHK-Cu targeting complementary angiogenic, cellular migration, and extracellular matrix remodeling pathways in preclinical research. All data presented reflects published research findings only.

🧬

Blend Type

Triple Regenerative Peptide Stack

📊

Components

BPC-157 + TB-500 + GHK-Cu

🔬

Primary Research Focus

Skin rejuvenation, tissue repair & collagen synthesis

🧪

Current Development Stage

Preclinical · Components individually studied

What Is GLOW?

🧠 Simple Explanation

GLOW is a triple-peptide blend that combines three well-researched compounds — BPC-157, TB-500, and GHK-Cu — each targeting a different aspect of tissue repair. Think of it as three specialists working together: one boosts blood vessel growth, another helps repair cells migrate to damaged areas, and the third stimulates collagen production and gene activity.

Researchers study this combination because the three peptides address complementary pathways, potentially producing effects greater than any single peptide alone. The 5:1:1 ratio (GHK-Cu:TB-500:BPC-157) is optimized for skin rejuvenation benefits.

🔬 Advanced Context

BPC-157 (15 amino acids, 1,419 Da) is a partial sequence of a larger protein found in human gastric juice. It promotes angiogenesis through the VEGFR2-Akt-eNOS pathway, enhances tissue granulation, and modulates nitric oxide signaling. Over 200 peer-reviewed publications since 1991 have investigated its tissue-protective properties across multiple organ systems.

TB-500 (43 amino acids, 4,963 Da) is a synthetic fragment of Thymosin Beta-4 that enhances cell migration via actin regulation, supports cytoskeletal remodeling, and reduces fibrotic scarring. Over 170 publications have examined its role in musculoskeletal healing and cardiac repair.

GHK-Cu (3 amino acids + Cu²⁺, 403 Da) is a naturally occurring copper-binding peptide found in human plasma. It stimulates type I & III collagen synthesis, modulates over 4,000 genes, and delivers copper ions to cells. Over 130 publications document its effects on skin tightening, wrinkle reduction, and wound healing.

The combination has not been evaluated in human clinical trials. Individual component safety profiles are favorable in preclinical studies — BPC-157 has no identified LD50, TB-500 is well-tolerated in animal models, and GHK-Cu has a long history of safe cosmetic use. BPC-157 and TB-500 are prohibited by WADA under the S0 category.

Molecular Profile

Component characteristics and storage parameters

BPC-157 Weight

1,419.5 Da (15 amino acids)

TB-500 Weight

4,963 Da (43 amino acids)

GHK-Cu Weight

403 Da (3 amino acids + Cu²⁺)

Total Peptides

3 distinct compounds

Blend Ratio

5:1:1 (GHK-Cu : TB-500 : BPC-157)

Available Dosage

70 mg per vial

Lyophilized Storage

-20°C for long-term stability

Reconstituted Storage

2–8°C; use within ~7 days

References: PubChem Databases

How It Works

Three complementary pathways targeting distinct regenerative mechanisms

STEP 01 →

VEGF Pathway — BPC-157

BPC-157 interacts with VEGFR2 receptors on endothelial cells, promoting blood vessel formation, enhancing tissue granulation, and modulating nitric oxide signaling through the Akt-eNOS cascade.

💡 Simple Translation

BPC-157 helps grow new blood vessels to damaged areas, improving blood flow so repair materials can reach where they're needed — like building new roads to a construction site.

STEP 02 →

Actin Regulation — TB-500

Thymosin Beta-4 (TB-500) upregulates actin polymerization, increasing cell migration speed (+85% in models), supporting cytoskeletal remodeling, and reducing fibrotic scarring during tissue repair.

💡 Simple Translation

TB-500 helps repair cells move faster toward damaged tissue by reorganizing their internal scaffolding — like giving construction workers faster vehicles to reach the job site.

STEP 03 →

Collagen & ECM — GHK-Cu

GHK-Cu stimulates type I & III collagen synthesis (70% increase vs. controls), modulates 4,000+ genes related to tissue remodeling, and delivers copper ions essential for enzymatic processes in extracellular matrix assembly.

💡 Simple Translation

GHK-Cu provides the building materials — it triggers collagen production and activates thousands of genes that help rebuild tissue structure, like supplying bricks, mortar, and blueprints all at once.

STEP 04

Synergistic Outcome

The three pathways converge: BPC-157 supplies vascular support, TB-500 mobilizes repair cells, and GHK-Cu provides structural rebuilding. Combined coverage spans angiogenesis, cell migration, anti-inflammatory activity, and ECM remodeling simultaneously.

💡 Simple Translation

Together, these three peptides address different phases of the healing process at the same time — rather than fixing one thing at a time, they work as a coordinated repair team.

Clinical Development Status

Current position in the regulatory pipeline (blend components)

✓
Preclinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Phase 4
6
FDA Approved

Individual components are at preclinical stage. BPC-157 has one registered Phase 1 trial (NCT02637284). The GLOW combination has not been evaluated in human clinical trials.

Research Timeline

Key milestones across GLOW component research

1973

GHK-Cu Discovery

GHK-Cu first identified in human plasma by Loren Pickart as an age-related copper-binding peptide

1991

BPC-157 Characterized

BPC-157 first isolated from human gastric juice at the University of Zagreb, Croatia

1999

TB-500 Wound Healing

Thymosin Beta-4 shown to accelerate wound healing with 61% faster re-epithelialization

2011

BPC-157 Tendon Research

Published findings on fibroblast outgrowth and cell migration (+70%) in tendon models

2015

GHK-Cu Tissue Remodeling

Comprehensive review of GHK-Cu's role in skin regeneration, collagen synthesis, and gene modulation

2018

GHK-Cu Gene Data Review

Landmark review published: regenerative actions of GHK-Cu in light of new gene data (4,000+ genes)

2022

WADA Prohibition

BPC-157 and TB-500 added to the World Anti-Doping Agency S0 prohibited substance list

2025

GLOW Protocol Research

Triple-peptide combination studied in preclinical models for complementary regenerative effects

What Does the Research Show?

Summary of investigational findings from individual component studies

📊Key Findings by Component
  • BPC-157: 200+ publications — 7× GHR upregulation by day 3 in tendon fibroblasts
  • TB-500: 170+ publications — 61% faster re-epithelialization vs. controls at 7 days
  • GHK-Cu: 130+ publications — 70% increase in collagen synthesis vs. controls
  • 500+ combined peer-reviewed studies across all three peptides
📈Research Metrics
  • 3 distinct regenerative pathways targeted simultaneously (VEGF + Actin + Collagen)
  • GHK-Cu modulates expression of 4,000+ human genes
  • TB-500 cell migration improvement of +85% in preclinical models
  • BPC-157 angiogenesis enhancement of +80% in tissue repair models
🔬Research Applications
  • Skin regeneration — collagen synthesis, wrinkle reduction, wound closure
  • Musculoskeletal repair — tendon, muscle, and soft tissue healing
  • Anti-inflammatory — all three peptides modulate inflammatory mediators
  • ECM remodeling — coordinated extracellular matrix deposition
🧪Safety Profile in Studies
  • BPC-157: No lethal dose (LD50) found in toxicology studies
  • TB-500: Well-tolerated in animal studies with no systemic toxicity
  • GHK-Cu: Long history of safe use in cosmetic formulations
  • Combination safety requires specific investigation — limited human data

Published Findings

Peer-reviewed studies on GLOW components with linked sources

StudyModelKey FindingYearSource
GHK-Cu regenerative & protective actionsReview (In vitro/In vivo)Stimulates collagen synthesis (+70%), modulates 4,000+ genes, promotes wound healing and skin remodeling2018Int J Mol Sci ↗
Thymosin Beta-4 cardiac repairAnimal (Mouse)Enhanced cell migration, actin regulation, and tissue repair in cardiac models2017Nature Sci Reports ↗
BPC-157 angiogenic growth factorsAnimal (Multiple)VEGFR2-mediated angiogenesis; tendon, ligament, muscle, and bone healing across GI and musculoskeletal models2018Curr Pharm Design ↗
BPC-157 nitric oxide systemAnimal (Rat)Anti-inflammatory activity through nitric oxide pathway modulation2016J Mol Medicine ↗
BPC-157 musculoskeletal soft tissueReview (Preclinical)Accelerated musculoskeletal soft tissue healing through multiple signaling pathways2019Cell Tissue Research ↗
GHK-Cu tissue remodelingReview (In vitro/Clinical)Skin tightening, wrinkle depth reduction, increased skin thickness in aged models2015Cosmetics (MDPI) ↗
TB-500 wound healing accelerationAnimal (Mouse)61% faster re-epithelialization vs. controls at 7 days; enhanced cell motility1999J Invest Dermatology ↗
BPC-157 tendon healing promotionAnimal (Rat)Dose-dependent fibroblast outgrowth, cell migration (+70%), survival under oxidative stress2011J Applied Physiology ↗
Review2018

GHK-Cu regenerative & protective actions

Stimulates collagen synthesis (+70%), modulates 4,000+ genes, promotes wound healing

View Source ↗
Animal (Mouse)1999

TB-500 wound healing acceleration

61% faster re-epithelialization vs. controls at 7 days; enhanced cell motility

View Source ↗
Animal (Rat)2011

BPC-157 tendon healing promotion

Fibroblast outgrowth, cell migration (+70%), survival under oxidative stress

View Source ↗
Review (Clinical)2015

GHK-Cu tissue remodeling

Skin tightening, wrinkle depth reduction, increased skin thickness in aged models

View Source ↗
Review (Preclinical)2019

BPC-157 musculoskeletal soft tissue healing

Accelerated healing through multiple signaling pathways

View Source ↗

⚠️ These studies examine individual GLOW components. Combination effects are based on mechanistic synergy, not direct clinical trials of the blend.

Research Applications

Areas of active investigation across GLOW component literature

  • Skin regeneration — GHK-Cu promotes collagen synthesis while BPC-157 and TB-500 support epithelial repair
  • Musculoskeletal repair — TB-500 enhances cell migration (+85%), BPC-157 supports tendon fibroblast viability
  • Anti-inflammatory — all three peptides modulate inflammatory mediators through distinct mechanisms
  • ECM remodeling — coordinated extracellular matrix deposition and reduced fibrotic scarring
  • Neurovascular interface — TB-500 and BPC-157 contribute to endothelial repair; GHK-Cu supports capillary growth
  • Anti-aging pathways — GHK-Cu gene modulation (4,000+ genes), wrinkle reduction, and skin thickness improvement
  • Wound healing — multi-phase approach spanning angiogenesis, cell migration, and collagen framework rebuilding
  • Antioxidant activity — GHK-Cu chelates free copper ions, BPC-157 stabilizes nitric oxide pathways

Delivery Methods Studied in Research

Investigational administration routes evaluated in published studies

Subcutaneous Injection

Primary administration route studied in preclinical GLOW research; localized tissue delivery

Oral Administration

BPC-157's stability in gastric acid (24+ hours) makes oral delivery a research interest

Topical Application

GHK-Cu has extensive history in topical cosmetic formulations for skin rejuvenation

Intraperitoneal Injection

Used in rodent models for systemic absorption studies of BPC-157 and TB-500

Dosing Information from Research

The GLOW blend uses a 5:1:1 ratio (GHK-Cu : TB-500 : BPC-157), optimized for skin rejuvenation research. Standard vial dosing follows protocol-specific formulations. Administration is typically once daily, with evening timing recommended to align with nighttime skin repair cycles when collagen synthesis peaks. Research protocols suggest 8–12 weeks for observable results.

⚠️ These figures are presented for scientific reference only and do not constitute usage recommendations. No standardized human dosing protocol has been established for the GLOW combination through controlled clinical trials.

Why It Arrives as a Powder

Understanding lyophilized formulation in the GLOW blend

❄️

Stability Preservation

Lyophilization removes water content, significantly reducing chemical degradation. This preserves the structural integrity of all three GLOW peptides during storage and transport.

📅

Extended Shelf Life

Dry powder form can maintain potency at -20°C for extended periods. Once reconstituted, GLOW should be refrigerated at 2–8°C and used within approximately 7 days.

🛡️

Degradation Prevention

Peptide bonds are susceptible to hydrolysis in aqueous environments. Removing the solvent eliminates this primary degradation pathway for all three components.

🔬

Laboratory Preparation

Reconstitution follows established protocols using bacteriostatic water or sterile saline, allowing precise concentration control appropriate for specific experimental designs.

💡

Light Protection

GLOW should be stored away from light to prevent photodegradation. Each component has slightly different stability profiles, so manufacturer guidelines should be followed.

Transparency & Quality Verification

Analytical standards applied to research-grade GLOW materials

🧪

Third-Party Analytical Testing

Independent laboratories perform comprehensive analysis on each production batch, ensuring unbiased verification of all three peptide components.

📊

Purity Verification (HPLC)

High-Performance Liquid Chromatography confirms peptide purity levels for BPC-157, TB-500, and GHK-Cu individually.

🔬

Identity Confirmation (Mass Spec)

Mass spectrometry validates molecular weight and structural identity of each GLOW component against expected profiles.

📋

Batch-Specific Certificates

Each lot is accompanied by a unique COA detailing purity percentage, lot number, test date, and testing laboratory for all three peptides.

📁

Documentation Transparency

All analytical results, testing methodologies, and laboratory credentials are made available for researcher review and institutional compliance.

🌡️

Storage Verification Standards

Cold-chain integrity monitoring ensures proper temperature maintenance from production through delivery, preserving stability of all blend components.

Related Peptides

Compounds commonly compared with GLOW or used in similar applications

Wolverine Stack

Peptide Blend

BPC-157 + TB-500 for angiogenesis & cell migration

KLOW Blend

Peptide Blend

BPC-157 + TB-500 + GHK-Cu + KPV (80mg)

BPC-157

Healing Peptide

Tissue repair & cytoprotection

TB-500

Healing Peptide

Cell migration & actin regulation

GHK-Cu

Copper Peptide

Skin remodeling & wound healing

LL-37

Antimicrobial Peptide

Innate immune defense

Frequently Asked Questions

Investigational context for common inquiries about GLOW

GLOW is a triple-peptide blend containing BPC-157 (a 15-amino acid gastric peptide, 1,419 Da), TB-500 (a 43-amino acid thymosin beta-4 fragment, 4,963 Da), and GHK-Cu (a copper tripeptide, 403 Da). Each peptide targets different but complementary regenerative mechanisms, making the combination relevant for multi-pathway tissue repair research.
The Wolverine Stack contains only BPC-157 and TB-500, focusing on angiogenesis and cell migration. GLOW adds GHK-Cu, which brings collagen synthesis, gene modulation (4,000+ genes), and copper delivery mechanisms. This third component extends the blend's research applications to include skin regeneration, anti-aging pathways, and extracellular matrix remodeling.
Individually, these peptides have extensive preclinical research: BPC-157 has 200+ publications studying wound healing, GI protection, and tissue repair; TB-500 has 170+ publications on cell migration and musculoskeletal healing; GHK-Cu has 130+ publications on collagen synthesis, gene expression, and skin regeneration. Combination research is emerging but less extensive.
The three peptides target overlapping but distinct pathways: (1) Angiogenesis — BPC-157 (VEGF) and GHK-Cu (capillary growth) promote blood vessel formation; (2) Cell migration — TB-500 regulates actin for cellular movement; (3) ECM remodeling — GHK-Cu stimulates collagen while TB-500 reduces fibrosis; (4) Anti-inflammatory — all three modulate inflammatory mediators through different mechanisms.
No. All three peptides are research compounds. BPC-157 and TB-500 are investigational peptides with no FDA approval and are banned by WADA (World Anti-Doping Agency) under the S0 category since 2022. GHK-Cu is used in cosmetic formulations but is not approved as a therapeutic agent. GLOW is intended for laboratory and preclinical research applications only.
BPC-157 has shown no lethal dose (LD50) in toxicity studies. TB-500 is well-tolerated in animal studies with no systemic toxicity detected. GHK-Cu has a long history of safe use in cosmetic products. However, because BPC-157 and TB-500 promote angiogenesis, there are theoretical concerns about potential effects on tumor development. Combination safety requires specific investigation, and long-term human data does not exist for any component.
Lyophilized (powder) form should be stored at -20°C for long-term stability. Once reconstituted, store at 2–8°C (refrigerated) and use within 7 days. Protect from light and avoid repeated freeze-thaw cycles. Each component has slightly different stability profiles, so follow manufacturer guidelines for specific formulations.
GLOW is studied in preclinical models for: (1) Skin regeneration and dermal remodeling; (2) Muscle and tendon repair; (3) Wound healing and tissue recovery; (4) Anti-inflammatory applications; (5) Extracellular matrix restoration. The combination approach targets multiple phases of the healing cascade simultaneously.
Research protocols typically use a 5:1:1 ratio (GHK-Cu:TB-500:BPC-157), optimized for skin rejuvenation benefits. Standard vial dosing follows protocol-specific formulations with once-daily administration. Evening timing is sometimes recommended to align with nighttime skin repair cycles when collagen synthesis peaks.
Research protocols suggest 8–12 weeks for visible results in skin rejuvenation models. BPC-157 growth hormone receptor expression was reported to increase 7-fold by day 3 in treated tissue. TB-500 showed 61% faster re-epithelialization vs. controls at 7 days. These timelines are specific to individual component studies and cannot be directly extrapolated to the combination.
Reported side effects in preclinical and limited human data include: injection site reactions (~10%), temporary skin flushing, mild headache (rare), and fatigue during initial use. No systemic toxicity has been identified for any individual component. Not everyone experiences these effects — individual responses vary based on dosage, duration, and personal factors.
Research-grade GLOW components are typically analyzed using High-Performance Liquid Chromatography (HPLC) for purity assessment and mass spectrometry for molecular identity confirmation. Each production batch should be accompanied by a Certificate of Analysis (COA) from an independent, third-party laboratory.

Sources & References

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data ↗

Pickart L, Margolina A · International Journal of Molecular Sciences (2018) · DOI: 10.3390/ijms19071987

Thymosin Beta 4 and Cardiac Repair ↗

Chi NC et al. · Scientific Reports (Nature) (2017)

BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing ↗

Seiwerth S et al. · Current Pharmaceutical Design (2018) · DOI: 10.2174/1381612824666180712110447

BPC-157 Interacts with the Nitric Oxide System ↗

Hsieh MJ et al. · Journal of Molecular Medicine (2016)

Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing ↗

Gwyer D et al. · Cell and Tissue Research (2019)

The Human Tripeptide GHK and Tissue Remodeling ↗

Pickart L et al. · Cosmetics (MDPI) (2015)

Thymosin Beta-4 Accelerates Wound Healing ↗

Malinda KM et al. · Journal of Investigative Dermatology (1999)

Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing ↗

Brcic L et al. · Journal of Physiology and Pharmacology (2011)

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration ↗

Chang CH et al. · Journal of Applied Physiology (2011) · DOI: 10.1152/japplphysiol.00945.2010

⚠️ Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims. BPC-157 and TB-500 are prohibited by WADA under the S0 category.

Search
Shopping Cart
GLOW
70 mg
Original price was: $199.99.Current price is: $149.99.
−
+